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Abstract
Aims To describe the prevalence of major cardiovascular disease (CVD) and risk factor control in a contemporary
population with Type 2 diabetes.
Methods We used data from the national registry in Scotland, Scottish Care Information-Diabetes, linked to hospital
admissions. Using descriptive statistics and logistic regression we described associations of risk factors with CVD. CVD
was defined based on diagnostic codes in primary or secondary care data for ischaemic heart disease, cerebrovascular
disease peripheral arterial disease, heart failure, cardiac arrhythmia, hypertensive heart disease and revascularization
procedures.
Results Among 248 400 people with Type 2 diabetes with a median age of 67.5 years (IQR 58.2, 76.1) and median
diabetes duration of 7.8 years (3.8, 13.0), 32% had prior CVD (35% of men, 29% of women). Median HbA1c overall
was 55 mmol/mol (7.2%), median SBP was 132 mmHg, median total cholesterol was 4.1 mmol/l and mean BMI was
32 kg/m2. Overall two-thirds (65% of men, 68% of women) have two or more of the following CVD risk factor
thresholds: HbA1c ≥ 53 mmol/mol (7%), SBP > 130 mmHg or DBP > 80 mmHg, total cholesterol ≥ 5 mmol/l or BMI
≥ 30 kg/m2, or were currently smoking. Overall 84% were taking anti-hypertensives and 75% a statin. Use of metformin
was common at 58%, but other diabetes drugs that reduce CVD were rarely used.
Conclusions There continues to be a high prevalence of CVD among people with Type 2 diabetes and a high level of
unmet need for risk factor control. This implies substantial scope for reducing the excess risk of CVD in diabetes through
improved management of known risk factors.
Diabet. Med. 36: 718–725 (2019)
Introduction
Total mortality rates are currently 40% higher in men and
50% higher in women with Type 2 diabetes mellitus
compared with the background population [1]. Cardiovas-
cular disease (CVD) remains the leading cause of loss of life
expectancy in Type 2 diabetes and rates remain elevated
compared with those without diabetes. Ongoing elevations in
risk have been reported in recent data from Scotland [2],
Sweden and the USA [3,4].
Key aspects of the prevention of primary and secondary
CVD in diabetes include smoking prevention, weight control,
blood pressure reduction, cholesterol lowering and glycaemic
control. With regards to glycaemic control, evidence of
vascular benefit has been demonstrated for metformin with
respect to myocardial infarction and pioglitazone with
respect to CVD; by contrast heart failure is increased [5–7].
For newer drugs, major cardiovascular outcome trials have
been conducted in recent years [8]. In four drugs from two
anti-diabetes drug classes, sodium glucose co-transporter 2
inhibitors (SGLT2i) and glucagon-like peptide 1 receptor
agonists (GLP-1RA), evidence of reduced risk of major CVD
events has been demonstrated. These four drugs are
canagliflozin (SGLT2i), empagliflozin (SGLT2i), liraglutide
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(GLP-1RA) and semaglutide (GLP-1RA). Drug labels and
clinical guidelines are being updated accordingly [9–16], and
it is hoped that the target of lowering HbA1c in Type 2
diabetes and the major goal of lowering the cause of excess
death will be increasingly achieved. For medical service
planning and to understand current standards of care, it is
important to quantify the unmet treatment needs of people
with Type 2 diabetes, including the prevalence of established
CVD and current drug treatment regimens in a broad and
representative Type 2 diabetes population. Accordingly, we
aimed to establish the current prevalence of established CVD
in a typical contemporary population with Type 2 diabetes.
Further, we wanted to investigate the scope for CVD
reduction through known risk factor control by identifying
the proportion of people having two, three, four or more risk
factors for CVD in the Scottish population with Type 2
diabetes. These data are timely given that the European
Association for the Study of Diabetes/American Diabetes
Association (EASD/ADA) are currently revising their joint
recommendations on hyperglycaemia management and
because these guidelines are apparently going to highlight
‘the need to consider the patient’s important comorbidities,
particularly cardiovascular disease or high cardiovascular
risk, in selecting glucose-lowering therapy’ [17].
Methods
Data sources
The Scottish Care Information-Diabetes (SCI-Diabetes) is a
register and database that covers almost all (> 99%) of those
in Scotland with a diagnosis of diabetes. It has been described
in detail previously [18]. It captures data from clinical
episodes and laboratory data in primary care, National
Health Service (NHS) hospital diabetes clinics, community
care and the national retinopathy screening programme.
Using the unique health service identifier, it has been linked
to hospital admissions data (Scottish Morbidity Record 01)
and to death data from the National Records of Scotland.
Availability of risk factor data was generally high, being
≥ 94% for HbA1c, total cholesterol, eGFR, smoking status,
blood pressure and retinopathy status. Availability was lower
for albuminuria (82%), BMI (80%), triglycerides (79%),
weight (72%) and LDL cholesterol (56%). However, there
was no difference in missingness for those with and without
CVD.
Participants
We defined the study cohort here as all people who were
alive, > 18 years of age and with a clinical diagnosis of Type
2 diabetes as of 1 January 2016.
Outcomes
To obtain information on CVD status we selected the
Scottish Morbidity Records inpatient and day case procedure
records (SMR01) which use the World Health Organization
(WHO) International Classification of Disease version 10
(ICD-10) for diagnosis (in earlier years version 9), and we use
the Classification of Interventions and Procedures (OPCS-4)
[19]. Each person’s records were queried for a look-back
period of 10 years.
CVD history was defined as having codes for main cause of
admission for any of chronic ischaemic heart disease (ICD-
10: I20–I25), cerebrovascular disease including transient
ischaemic attack (ICD-10: I60–I69 and G45), peripheral
arterial disease (ICD-10: I70.2 and I73.9), heart failure (III.0,
I13 I50), cardiac arrhythmia (I48, I49), hypertensive heart
disease (I13.0, I15.0) or procedure codes for revasculariza-
tion procedures of coronary, carotid or lower limb arteries.
Primary care records were also queried for corresponding
Read codes for coronary heart disease (CHD), cerebrovas-
cular disease and revascularization procedures, peripheral
vascular disease and atrial fibrillation [20].
Other risk factor and covariate data were obtained from
SCI-Diabetes on retinopathy screening status, HbA1c, body-
weight, BMI, blood pressure, estimated GFR (eGFR), plasma
total cholesterol, triglycerides and urinary albumin–crea-
tinine ratio. The value for these variables nearest in time to 1
January 2016 was used, with a maximum look-back period
of 2 years. The most recent of the observational records in
the 2-year period was selected for each individual. Age was
calculated at 1 January 2016.
Statistical analysis
Simple summary statistics were used to describe the preva-
lence and distributions of disease and risk factors. We
counted the number of the following risk factor thresholds
each person had: HbA1c ≥ 53 mmol/mol (7%), SBP
> 130 mmHg or DBP > 80 mmHg, total cholesterol ≥ 5
mmol/l or BMI ≥ 30 kg/m2, or current smoking. For HbA1c
What’s new?
• There have been substantial advances in the manage-
ment and prevention of cardiovascular disease in
diabetes. To understand where unmet needs lie, it is
important to understand the current burden of cardio-
vascular disease and the levels of treated and untreated
risk factors.
• In this paper, we show that there continues to be a high
prevalence of cardiovascular disease among people with
Type 2 diabetes and a high level of unmet need for risk
factor control. This implies substantial scope for
reducing the excess risk of cardiovascular disease in
diabetes through improved management of known risk
factors.
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and blood pressure, these thresholds were chosen to reflect
typical clinical guideline intervention levels [5,21]; BMI and
total cholesterol were chosen to reflect more extreme lack of
control, because most people with Type 2 diabetes require
interventions for BMI and warrant lipid-lowering therapy.
Because for some people, target BP is < 140/80 mmHg, we
also report these data using this threshold. Logistic regression
was used to quantify the differences in risk factors in those
with and without prior CVD.
Results
Some 248 400 people with Type 2 diabetes were included.
Almost a third (32%) of those with Type 2 diabetes had
established CVD, the prevalence being 29% (31 635/
108 259) in women and 35% in men (48 962/140 141)
(Table 1). The prevalence rose from 15% (11 249/72 894)
in those aged < 60 years to 53% (19 987/38 096) in those
aged ≥ 80 years. In this cross-sectional analysis, those with
Table 1 Demographic characteristics and risk factor levels by cardiovascular disease (CVD) status in people with Type 2 diabetes
Variable Established CVD No CVD Total
Total included 80 597 (32.45) 167 803 (67.55) 248 400 (100)
Gender
Male 48 962 (60.4) 91 179 (54.3) 140 141 (56.4)
Female 31 635 (39.3) 76 624 (45.7) 108 259 (43.6)
Age
< 60 11 249 (14.0) 61 645 (36.7) 72 894 (29.3)
60–69 21 647 (26.9) 50 246 (29.9) 71 893 (28.9)
70–79 27 714 (34.4) 37 803 (22.5) 65 517 (26.4)
80+ 19 987 (24.8) 18 109 (10.8) 38 096 (15.3)
Age at study day (years)* 72.8 (65.1, 80.0) 64.7 (55.6, 73.3) 67.5 (58.2, 76.1)
Age at diabetes diagnosis (years)* 61.9 (53.5, 69.7) 56.0 (47.4, 64.6) 58.0 (49.2, 66.5)
Diabetes duration (years)* 9.5 (4.8, 15.0) 7.1 (3.4, 12.0) 7.8 (3.8, 13.0)
HbA1c (mmol/mol)* 54 (47, 66) 55 (47, 67) 55 (47, 66)
HbA1c (%)* 7.1 (6.5, 8.2) 7.2 (6.5, 8.3) 7.2 (6.5, 8.2)
Systolic BP (mmHg)* 132 (122, 140) 133 (124, 140) 132 (124, 140)
Diastolic BP (mmHg)* 73 (67, 80) 77 (70, 80) 76 (70, 80)
MDRD eGFR (ml min1 1.73 m2)* 68.5 (53.0, 84.3) 79.0 (65.2, 93.4) 75.8 (61.0, 90.9)
CKDEpi eGFR (ml min1 1.73 m2)* 70.1 (52.9, 85.9) 83.6 (67.6, 95.8) 79.7 (62.3, 93.1)
BMI (kg/m2)* 30.6 (27.3, 34.6) 31.3 (27.7, 35.8) 31.1 (27.6, 35.4)
Weight (kg)* 88.0 (76.0, 100.0) 89.5 (77.3, 103.0) 89.0 (77.0, 102.0)
Total cholesterol (mmol/l)* 3.9 (3.3, 4.6) 4.2 (3.6, 5.0) 4.1 (3.5, 4.9)
LDL cholesterol (mmol/l)* 1.9 (1.4, 2.4) 2.1 (1.6, 2.7) 2.0 (1.5, 2.6)
Triglycerides (mmol/l)* 1.8 (1.3, 2.5) 1.7 (1.2, 2.5) 1.7 (1.3, 2.5)
Albuminuric status
Normoalbuminuric 46 288 (69.3) 111 602 (81.3) 157 890 (77.4)
Microalbuminuric 16 916 (25.3) 22 805 (16.6) 39 721 (19.5)
Macroalbuminuric 3562 (5.3) 2924 (2.1) 6486 (3.2)
Renal status
CKD-EPI CKD Stage 1 14 214 (18.1) 60 156 (37.1) 74 370 (30.9)
CKD-EPI CKD Stage 2 37 090 (47.3) 75 436 (46.5) 112 526 (46.8)
CKD-EPI CKD Stage 3 23 635 (30.2) 24 524 (15.1) 48 159 (20.0)
CKD-EPI CKD Stage 4/5 3423 (4.4) 2074 (1.3) 5497 (2.3)
MDRD CKD Stage 1 14 112 (18.0) 49 088 (30.3) 63 200 (26.3)
MDRD CKD Stage 2 36 656 (46.8) 84 104 (51.9) 120 760 (50.2)
MDRD CKD Stage 3 24 609 (31.4) 27 164 (16.7) 51 773 (21.5)
MDRD CKD Stage 4/5 2985 (3.8) 1834 (1.1) 4819 (2.0)
eGFR < 60 ml min1 1.73 m2 28 402 (35.2) 29 682 (17.7) 58 084 (23.4)
Receiving renal replacement therapy 946 (1.2) 582 (0.3) 1528 (0.6)
Retinopathy status
None 55 588 (73.3) 121 389 (77.4) 176 977 (76.1)
Mild or moderate 15 137 (19.9) 27 293 (17.4) 42 430 (18.2)
Pre-proliferative or worse 5159 (6.8) 8065 (5.1) 13 224 (5.7)
Current smoker 14 371 (17.9) 28 640 (17.1) 43 011 (17.4)
HbA1c ≥ 53 mmol/mol 43 890 (55.8) 92 976 (57.3) 136 866 (56.8)
HbA1c ≥ 58 mmol/mol 32 185 (40.9) 68 374 (42.1) 100 559 (41.7)
SBP >130 mmHg or DBP >80 mmHg 43 715 (54.2) 100 228 (59.7) 143 943 (57.9)
SBP >140 mmHg or DBP >80 mmHg 23 183 (28.8) 56 659 (33.8) 79 842 (32.1)
Total cholesterol ≥ 5 mmol/l 130 66 (16.9) 40 708 (25.5) 53 774 (22.7)
Currently prescribed a statin 67 378 (83.6) 119 381 (71.1) 186 759 (75.2)
BMI ≥ 30 kg/m2 34 227 (42.5) 81 190 (48.4) 115 417 (46.5)
Currently on anti-hypertensives 77 936 (96.7) 129 737 (77.3) 207 673 (83.6)
Values are given as N (%) unless indicated otherwise; *values are median (IQR). CKD, chronic kidney disease; CKD-EPI, Chronic Kidney
Disease Epidemiology.
720
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Cardiovascular disease and risk factor prevalence in Type 2 diabetes  S. McGurnaghan et al.
established CVD were older, more likely to be male and had
longer diabetes duration (Table 1). Adjusted for age, sex and
diabetes duration, those with CVD had significantly
(P < 0.01) higher BMI, higher HbA1c, were more likely to
have albuminuria and currently smoking, and had lower
eGFR. Those with CVD had lower age, diabetes duration
and sex-adjusted achieved SBP (P < 0.01) and lower choles-
terol levels (P < 0.01) compared with those without a prior
history of CVD, on a background of significantly more anti-
hypertensive and statin therapy (both P < 0.01). Overall,
58% had a SBP > 130 mmHg or a DBP > 80 mmHg, with
this prevalence being 54% in those with CVD and 60% in
those without CVD. Overall, almost all (97%) of those with
CVD were taking at least one anti-hypertensive drug com-
pared with 77% of those without CVD (Table 1). Of those
with CVD, 2% were hypertensive and not prescribed any
blood pressure drug, whereas among those without CVD,
11% were hypertensive and not taking any anti-hypertensive
drug (Fig. 1). Overall, 75% were currently prescribed a
statin. Overall 23% (17% of those with CVD and 26% of
those without) had a total cholesterol ≥ 5 mmol/l (Table 1).
Among those with CVD, 6% had a total cholesterol ≥ 5
mmol/l and were not taking a statin. Among those without
CVD, 11% had a total cholesterol ≥ 5 mmol/l and were not
taking a statin (Fig. 1).
We counted the number of the following risk factor
thresholds exceeded by each person; HbA1c ≥ 53 mmol/mol,
SBP > 130 mmHg or DBP > 80 mmHg, total cholesterol ≥ 5
mmol/l or BMI > 30 kg/m2, or current smoking. Overall,
65% of men and 68% of women with Type 2 diabetes have
two or more of these risk factor thresholds (Table 2;
Table S1). Among those with CVD, 62% had at least two
risk factors; in those without CVD, the value was 69%. At all
ages and in both sexes, the proportions exceeding these
thresholds were high (Table 2; Table S1). In the oldest group,
aged ≥ 80 years, the proportions were lowest at 45% of men
and 52% of women exceeding two or more thresholds. This
reflected significantly lower proportions exceeding the HbA1c
0
25
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%
Total cholesterol and medication
≥ 5; no statin
≥ 5; statin
< 5; statin
< 5; no statin
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FIGURE 1 Statin and anti-hypertensive use by risk factor threshold and cardiovascular disease (CVD) status.
Table 2 Number of risk factor thresholds exceeded by cardiovascular disease (CVD) status
Number of risk factors 0 1 2 3 4 5 Total
Established and no CVD
All 21 308 (8.6) 62 376 (25.1) 85 308 (34.3) 59 609 (24.0) 17 803 (7.2) 1996 (0.8) 248 400 (100)
Male 12 605 (9.0) 36 273 (25.9) 48 695 (34.7) 32 583 (23.3) 9016 (6.4) 969 (0.7) 140 141 (56.4)
Female 8703 (8.0) 26 103 (24.1) 36 613 (33.8) 27 026 (25.0) 8787 (8.1) 1027 (0.9) 108 259 (43.6)
Established CVD
All 8231 (10.2) 22 658 (28.1) 27 866 (34.6) 16 945 (21.0) 4441 (5.5) 456 (0.6) 80 597 (100)
Male 5152 (10.5) 14 182 (29.0) 17 026 (34.8) 10 037 (20.5) 2342 (4.8) 223 (0.5) 48 962 (60.7)
Female 3079 (9.7) 8476 (26.8) 10 840 (34.3) 6908 (21.8) 2099 (6.6) 233 (0.7) 31 635 (39.3)
No CVD
All 13 077 (7.8) 39 718 (23.7) 57 442 (34.2) 42 664 (25.4) 13 362 (8.0) 1540 (0.9) 167 803 (100)
Male 7453 (8.2) 22 091 (24.2) 31 669 (34.7) 22 546 (24.7) 6674 (7.3) 746 (0.8) 91 179 (54.3)
Female 5624 (7.3) 17 627 (23.0) 25 773 (33.6) 20 118 (26.3) 6688 (8.7) 794 (1.0) 76 624 (45.7)
Values are given as N (%).
The following risk factor thresholds were used: SBP > 130 mmHg or DBP > 80 mmHg; HbA1c ≥ 53 mmol/mol (7%); BMI ≥ 30 kg/m
2; total
cholesterol ≥ 5 mmol/l; current smoker.
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and BMI thresholds, and less smoking compared with
younger age groups (Fig. S1; P < 0.01 for comparison with
the youngest group adjusted for sex and diabetes duration).
There was more hypertension and more current anti-
hypertensive therapy in the older age group (P < 0.01
compared with the youngest age group). The proportions
with total cholesterol ≥ 5 mmol/l fell from 35% in those
aged < 50 years to 16% in those aged ≥ 80 years (P < 0.01
compared with those aged < 50 years). Statins were pre-
scribed in 55% of those aged < 50 years, 80% in those aged
50–79 years and 70% in those aged ≥ 80 years. As expected,
albuminuria and low eGFR were more common at older ages
(data not shown). When a cut-off of 140 mmHg rather than
130 mmHg was used for SBP the prevalence of those
exceeding two or more thresholds was 57% overall.
The number of diabetes drugs used was highest in the 50–
70-year age groups, falling off thereafter (Table 3; Table S2).
The number of diabetes drugs used was similar in those with
and without CVD, but the use of insulin was higher in those
with CVD compared with those without. Metformin and
pioglitazone use (99% of the thiazolidinedione/other cate-
gory shown in Table 4 comprised pioglitazone) was slightly
lower in those with than without CVD (Table 4). Overall
just 2.4% of those with CVD and 2.9% of those without
were on a GLP-1 agonist and just 1.4% and 2.2% of those
with and without CVD respectively were on an SGLT2
inhibitor.
Discussion
In this study, we find a high prevalence of established CVD in
people with Type 2 diabetes, with a third of those with
diabetes having had prior CVD. In both those with and those
without a history of CVD there remain high levels of unmet
need with regard to risk factor control. Overall, 65% of men
and 68% of women with Type 2 diabetes have two or more
of these risk factor thresholds. At present, HbA1c targets
< 58 mmol/l are set for most people with Type 2 diabetes
and targets < 53 mmol/l, where safely achievable, are set in
US and UK guidelines [5]. However, as shown here, just over
half achieve the 58 mmol/l target. Approximately one-third
of people already receive two or more diabetes drugs, but
these HbA1c levels suggest that there is scope, at least in
some, for intensification of therapy or switching to different
drug classes where existing therapy is not achieving targets.
Metformin and pioglitazone, for which there are data
showing a reduction in CVD, were slightly less commonly
used in those with CVD than in those without, and the
prevalence of use of pioglitazone was very low at < 5%. Of
note, the least utilized anti-diabetes drug classes for people
Table 3 Number of diabetes drugs by cardiovascular (CVD) status
Number of diabetes drugs 0 1 2 3+ Total
Established and no CVD
All 75 648 (30.5) 89 571 (36.1) 57 464 (23.1) 25 717 (10.4) 248 400 (100)
Male 40 244 (28.7) 49 640 (35.4) 33 844 (24.1) 16 413 (11.7) 140 141 (56.4)
Female 35 404 (32.7) 39 931 (36.9) 23 620 (21.8) 9304 (8.6) 108 259 (43.6)
Established CVD
All 24 605 (30.5) 29 625 (36.8) 18 693 (23.2) 7674 (9.5) 80 597 (100)
Male 13 956 (28.5) 17 654 (36.1) 11 957 (24.4) 5395 (11.0) 48 962 (60.7)
Female 10 649 (33.7) 11 971 (37.8) 6736 (21.3) 2279 (7.2) 31 635 (39.3)
No CVD
All 51 043 (30.4) 59 946 (35.7) 38 771 (23.1) 18 043 (10.8) 167 803 (100)
Male 26 288 (28.8) 31 986 (35.1) 21 887 (24.0) 11 018 (12.1) 91 179 (54.3)
Female 24 755 (32.3) 27 960 (36.5) 16 884 (22.0) 7025 (9.2) 76 624 (45.7)
Values are given as N (%).
Table 4 Use of diabetes drugs by cardiovascular disease (CVD) status
Drug Established CVD No CVD Total
Insulin 12 203 (15.1) 14 842 (8.8) 27 045 (10.9)
Metformin 42 641 (52.9) 100 178 (59.7) 142 819 (57.5)
Sulphonylurea 21 842 (27.1) 43 476 (25.9) 65 318 (26.3)
DPP-4 inhibitor 8024 (10.0) 17 054 (10.2) 25 078 (10.1)
GLP-1 agonist 1952 (2.4) 4866 (2.9) 6818(2.7)
SGLT2 inhibitor 1158 (1.4) 3741 (2.2) 4899(2.0)
TZD/other 2852 (3.5) 9076 (5.4) 11 928 (4.8)
Values are given as N (%). DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide 1; SGLT2, sodium glucose co-transporter 2; TZD,
thiazolidinediones.
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with Type 2 diabetes in Scotland at the time of the study
(2016) were the SGLT2i and GLP-1 agonists. Because anti-
diabetes drugs in these classes have been shown to reduce
CVD risk and CVD mortality, and this is now influencing
guidelines, the pattern should change in the future. In the
guidelines, BP targets are set at 130–140 mmHg for SBP and
80–90 mmHg for DBP, depending on CVD history. How-
ever, fewer than half are achieving the target of < 130/
80 mmHg and two-thirds the target of < 140/80 mmHg [5–
7]. This is despite the vast majority of people with Type 2
diabetes being on anti-hypertensive therapy. So, recognizing
the need for treatment is not the challenge, rather there may
be scope for further intensification where this is tolerated.
Similarly, most people are receiving statin therapy, yet total
cholesterol levels are high at a mean of 4.1 mmol/l, with
21% exceeding 5 mmol/l. This also suggests scope for more
intensive lipid-lowering therapy where this is tolerated.
Guidelines also suggest intervention for obesity, but more
than half of the people in this study remain obese. Further-
more, a sizeable proportion are current smokers, suggesting
scope for more intensive support for smoking cessation. The
proportions exceeding risk factor thresholds for HbA1c, BMI,
total cholesterol and smoking were lowest in those with an
attained age of 80 years or more. This could reflect a
survivor effect, or that some who develop diabetes in later
age have less-aggressive diabetes phenotypes, as recently
discussed [22]. We cannot discern which of these phenomena
may underlie this lower risk factor prevalence at older ages,
but we note that in contrast to anti-hypertensive usage the
intensity of diabetes drug use and statin fell in the older age
bands, indicating treatment rates do not explain the HbA1c
and lower cholesterol. We cannot comment with these data
on the appropriateness of these lower treatment rates at older
ages, but they may reflect the emphasis in national guidelines
that diabetes care be tailored to the person’s individual needs
‘taking into account their personal preferences, comorbidi-
ties, risks from polypharmacy, and their ability to benefit
from long-term interventions because of reduced life
expectancy’ [5].
That further scope for narrowing the gap in life expectancy
associated with Type 2 diabetes may be achievable by more
intensified clinical management of this disease is emphasized
by a recent analysis from the USA, which found that those
with diabetes who met modest treatment goals for HbA1c,
non-HDL cholesterol and blood pressure had a 37% lower
mortality than those who did not [23]. In that analysis,
almost half of those with Type 2 diabetes had HbA1c
> 53 mmol/mol (7%) and 14% had an HbA1c of
≥ 75 mmol/mol (9%). In a recent survey from Denmark of
people with Type 2 diabetes being cared for in primary care,
the risk factor data are overall very similar to these data from
Scotland [24]. Specifically, mean age was 4 years higher
(72 years), smoking prevalence was similar (17%), mean
HbA1c was slightly (3 mmol/mol) lower, SBP was 2 mmHg
lower, DBP was the same, and total cholesterol was just
0.1 mmol/l lower, whereas rates of lipid-lowering drug and
anti-hypertensive use were very similar. The main difference
in current diabetes drugs use was that in Denmark fewer
people (8% compared with 26%) were using sulphonylureas
and more (19% compared with 11%) were on insulin
therapy. Compared with a summary from the US NHANES
survey data for 2014 for all types of diabetes combined, the
risk factor levels are broadly similar, with mean BMI being
~ 3 kg/m2 higher in the USA, blood pressure ~ 9 mmHg
lower and total cholesterol ~ 0.7 mmol/l higher in their 2014
survey compared with these data from Scotland [25].
Surprisingly, reported use of anti-hypertensive (58%) and
lipid-lowering drugs (50%) was much lower in that study
than in Scotland. In NHANES, 57% were achieving an
HbA1c < 53 mmol/mol (7%) compared with 43% in Scot-
land. There were 15% current smokers compared with 17%
in Scotland [25].
Our definition of CVD was wide, capturing not just CHD
and cerebrovascular disease, but also cardiac arrhythmia,
peripheral arterial disease and related revascularizations.
Restricting the definition to prior CHD or cerebrovascular
disease or coronary revascularization procedures or heart
failure would yield a prevalence of 28%. On the other hand,
if we define CVD based on the entry criteria in the LEADER
trial, then 44% of our population met this definition [12].
Clearly, the burden of established CVD is large under any
definition used.
Our data are of substantial interest in understanding what
percentage of people with diabetes have unmet need for CVD
prevention therapies. In particular, although new diabetes
drugs are being licensed based on efficacy for HbA1c and lack
of harm for CVD, there is now evidence of cardiovascular
benefit for some. New diabetes therapies that have shown
benefit with regard to CVD reduction offer scope for
simultaneous improvement in HbA1c while lowering CVD
risk. For the SGLT2 inhibitor empagliflozin the hazard ratio
(HR) for CVD was 0.86 (95% CI 0.74 to 0.99) [9] and for
canagliflozin it was 0.86 (0.75 to 0.97) [10]. For the GLP-1
agonist semaglutide vs. placebo the HR was 0.74 (0.58 to
0.95) for CVD [11] and for liraglutide vs. placebo the HR
was 0.87 (0.78 to 0.97) [12]; for lixisenatide vs. placebo the
HR was 1.02 (0.89 to 1.17) [13]. Trials of the DPP-4
inhibitors sitagliptin [14], alogliptin [15] and saxagliptin [16]
have not shown these reductions. Further large cardiovascu-
lar outcome trials will report in the next 2 years [8,26]. These
data from 2016 predate changes in guidelines and licencing
for many of the new diabetes drugs and show very low rates
of use of diabetes drugs with evidence of CVD prevention
other than metformin.
This study aimed to give a brief contemporary snapshot of
Type 2 diabetes and its management. Limitations are that for
some risk factors data were incomplete. However, the
similarity in missingness between CVD status groups and
the fact that the sample size with available data is large in all
strata, means that imputation is not needed, and our
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estimates have precision and are free of missing data bias or
confounding. Another limitation is that we do not have data
on why those with elevated risk factors seem to be insuffi-
ciently treated based on their risk factors – i.e. whether this is
under-prescribing, non-adherence or side-effect issues. A key
aspect of our study is that the sample is large and represen-
tative of the Scottish population.
Conclusion
We found that there continues to be a high prevalence (32%)
of CVD among people with diabetes and a high level of
unmet need with regard to risk factor control. This implies
substantial scope for further reduction in the relative risk of
CVD associated with diabetes through adherence to healthy
lifestyles and use of drugs that reduce CVD and control of
known risk factors, including but not restricted to HbA1c.
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